- Home
- WHLR vs INDP Comparison
WHLR vs INDP Comparison
Compare WHLR & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHLR | INDP |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.0M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | WHLR | INDP |
|---|---|---|
| Price | $2.41 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.4M | 35.5K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 61.36 | N/A |
| Revenue | ★ $101,834,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.36 | $1.65 |
| 52 Week High | $6,719.86 | $47.60 |
Technical Indicators
Market Signals| Indicator | WHLR | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 45.20 | 39.10 |
| Support Level | $2.36 | $2.39 |
| Resistance Level | $6.85 | $2.94 |
| Average True Range (ATR) | 0.70 | 0.20 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 1.00 | 8.29 |
Price Performance
Historical ComparisonAbout WHLR Wheeler Real Estate Investment Trust Inc.
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.